Literature DB >> 23858029

Inhibition of CD8+ T cell-derived CD40 signals is necessary but not sufficient for Foxp3+ induced regulatory T cell generation in vivo.

Danya Liu1, Ivana R Ferrer, Michael Konomos, Mandy L Ford.   

Abstract

Current models of CD4(+) T cell help suggest a major role for CD154 binding to CD40 expressed on dendritic cells, with a lesser role for direct T:T interactions via CD40 expressed on CD8(+) T cells. However, the contribution of CD8(+) T cell-derived CD40 signals during the donor-reactive T cell response to a transplant has never been studied. In this study, we examined the graft-rejection kinetics and CD4(+) and CD8(+) donor-reactive T cell responses under conditions in which CD40 was genetically ablated only on APC, as well as under conditions in which CD40 was genetically ablated only on donor-reactive CD8(+) T cells. Our results revealed a significant role for CD8(+) T cell-expressed CD40 in the augmentation of donor-reactive CD8(+) T cell responses following transplantation and showed that CD40 expressed on CD8(+) T cells must be inhibited to allow conversion of CD4(+) T cells into induced regulatory T cells. Thus, this study identifies a major role for CD8(+) T cell-derived CD40 signals as a critical switch factor that both promotes optimal differentiation of cytokine-producing CD8(+) effector T cell responses and inhibits the differentiation of Ag-specific Foxp3(+) induced regulatory T cells in vivo.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23858029      PMCID: PMC3735715          DOI: 10.4049/jimmunol.1300267

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  34 in total

1.  Asialo GM1(+) CD8(+) T cells play a critical role in costimulation blockade-resistant allograft rejection.

Authors:  J Trambley; A W Bingaman; A Lin; E T Elwood; S Y Waitze; J Ha; M M Durham; M Corbascio; S R Cowan; T C Pearson; C P Larsen
Journal:  J Clin Invest       Date:  1999-12       Impact factor: 14.808

Review 2.  The CD40/CD154 receptor/ligand dyad.

Authors:  U Schönbeck; P Libby
Journal:  Cell Mol Life Sci       Date:  2001-01       Impact factor: 9.261

3.  Development of a novel transgenic mouse for the study of interactions between CD4 and CD8 T cells during graft rejection.

Authors:  Benjamin D Ehst; Elizabeth Ingulli; Marc K Jenkins
Journal:  Am J Transplant       Date:  2003-11       Impact factor: 8.086

Review 4.  CD40/CD154 interactions at the interface of tolerance and immunity.

Authors:  Sergio A Quezada; Lamis Z Jarvinen; Evan F Lind; Randolph J Noelle
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

5.  A role for CD40 expression on CD8+ T cells in the generation of CD8+ T cell memory.

Authors:  Christine Bourgeois; Benedita Rocha; Corinne Tanchot
Journal:  Science       Date:  2002-09-20       Impact factor: 47.728

6.  Fc-dependent depletion of activated T cells occurs through CD40L-specific antibody rather than costimulation blockade.

Authors:  Nicola J Monk; Roseanna E G Hargreaves; James E Marsh; Conrad A Farrar; Steven H Sacks; Maggie Millrain; Elizabeth Simpson; Julian Dyson; Stipo Jurcevic
Journal:  Nat Med       Date:  2003-09-14       Impact factor: 53.440

7.  CD40/CD154 blockade inhibits dendritic cell expression of inflammatory cytokines but not costimulatory molecules.

Authors:  Ivana R Ferrer; Danya Liu; David F Pinelli; Brent H Koehn; Linda L Stempora; Mandy L Ford
Journal:  J Immunol       Date:  2012-09-21       Impact factor: 5.422

8.  T cell receptor antagonist peptides induce positive selection.

Authors:  K A Hogquist; S C Jameson; W R Heath; J L Howard; M J Bevan; F R Carbone
Journal:  Cell       Date:  1994-01-14       Impact factor: 41.582

9.  Cutting edge: long-lived CD8 memory and protective immunity in the absence of CD40 expression on CD8 T cells.

Authors:  Joseph C Sun; Michael J Bevan
Journal:  J Immunol       Date:  2004-03-15       Impact factor: 5.422

10.  CD40-deficient, influenza-specific CD8 memory T cells develop and function normally in a CD40-sufficient environment.

Authors:  Byung O Lee; Louise Hartson; Troy D Randall
Journal:  J Exp Med       Date:  2003-12-01       Impact factor: 14.307

View more
  8 in total

Review 1.  New insights into T-cell cosignaling in allograft rejection and survival.

Authors:  Scott M Krummey; Mandy L Ford
Journal:  Curr Opin Organ Transplant       Date:  2015-02       Impact factor: 2.640

2.  Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

Authors:  S C Kim; W Wakwe; L B Higginbotham; D V Mathews; C P Breeden; A C Stephenson; J Jenkins; E Strobert; K Price; L Price; R Kuhn; H Wang; A Yamniuk; S Suchard; A B Farris; T C Pearson; C P Larsen; M L Ford; A Suri; S Nadler; A B Adams
Journal:  Am J Transplant       Date:  2017-02-25       Impact factor: 8.086

Review 3.  Novel insights into anti-CD40/CD154 immunotherapy in transplant tolerance.

Authors:  David F Pinelli; Mandy L Ford
Journal:  Immunotherapy       Date:  2015       Impact factor: 4.196

Review 4.  T Cell Cosignaling Molecules in Transplantation.

Authors:  Mandy L Ford
Journal:  Immunity       Date:  2016-05-17       Impact factor: 31.745

Review 5.  Targeting co-stimulatory pathways: transplantation and autoimmunity.

Authors:  Mandy L Ford; Andrew B Adams; Thomas C Pearson
Journal:  Nat Rev Nephrol       Date:  2013-10-08       Impact factor: 28.314

Review 6.  Update on CD40 and CD154 blockade in transplant models.

Authors:  Tianshu Zhang; Richard N Pierson; Agnes M Azimzadeh
Journal:  Immunotherapy       Date:  2015-08-13       Impact factor: 4.196

7.  The Inhibition of CD40/CD154 Costimulatory Signaling in the Prevention of Renal Transplant Rejection in Nonhuman Primates: A Systematic Review and Meta Analysis.

Authors:  Steven Perrin; Marianne Magill
Journal:  Front Immunol       Date:  2022-04-07       Impact factor: 8.786

8.  CD40-mediated maintenance of immune homeostasis in the adipose tissue microenvironment.

Authors:  Zuoan Yi; Laura L Stunz; Gail A Bishop
Journal:  Diabetes       Date:  2014-03-19       Impact factor: 9.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.